Research progress on role of anticoagulant drugs in prevention and treatment of cancer-associated venous thromboembolism
10.3969/j.issn.1006-5725.2025.05.022
- VernacularTitle:肿瘤相关静脉血栓栓塞症防治基石
- Author:
Xiaoli QIN
1
;
Xiurong GAO
;
Qin HE
;
Zhumei LUO
;
Qian JIANG
Author Information
1. 成都市第三人民医院 药学部(四川 成都 610031)
- Publication Type:Journal Article
- Keywords:
cancer-associated venous thromboembolism;
anticoagulant drugs;
heparin;
low molecu-lar weight heparin;
new anticoagulants
- From:
The Journal of Practical Medicine
2025;41(5):766-772
- CountryChina
- Language:Chinese
-
Abstract:
Cancer-associated venous thromboembolism(CAT)refers to the presence of venous thromboem-bolism including deep vein thrombosis and pulmonary embolism in patients with malignant cancer.Studies have indicated that CAT has become the second leading cause of death among cancer patients.Similar to other methods used to prevent and treat venous thromboembolism,anticoagulation remains to be the primary approach for CAT.However,the occurrence of CAT is influenced by various factors such as tumor type,staging,complications,treat-ment,and prognosis.This complexity makes the prevention and management of CAT more difficult and challeng-ing.This article reviews the classification of commonly used anticoagulant drugs in clinical practice,emphasizing the current status and advancements in their application for the prevention and treatment of cancer-related venous thromboembolism in order to provide valuable reference for clinical medication.
